The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.
|Articles|April 15, 2013
GE Healthcare Awarded Contract to Design New Plant-Based Biopharmaceutical Facility in Brazil
Author(s)BioPharm International Editors
New facility for Bio-Manguinhos will use plant-based protein expression technology.
Advertisement
GE Healthcare and iBio Inc.
The alliance combines iBio’s plant-based manufacturing platform, iBioLaunch with GE Healthcare’s capabilities in process design and biopharmaceutical and vaccine manufacturing technologies. Bio-Manguinhos/Fiocruz is a manufacturer of immunobiologicals for public health needs, primarily to support programs of the Brazilian Ministry of Health. It has invested in the development of bioprocess technologies, such as iBioLaunch, through a codevelopment agreement with iBio and its research and development collaborator the Fraunhofer USA Center for Molecular Biotechnology, which will continue to play a role in advancing iBioLaunch. The iBioLaunch platform is a proprietary technology for the development and production of biologics using transient gene expression in unmodified green plants.
Advertisement
Related to this article
Gilead agrees to acquire PepStar’s oral IL-23R peptide program for $1.275 billion, Zymeworks licenses its DLL3-targeted trispecific T-cell engager ZW209 to Roche, and the US Treasury proposes adding biotechnology to its outbound investment restrictions.
FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.
Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.
Roche gains exclusive global rights to ZW209, a DLL3×CD3×CD28 trispecific T-cell engager designed for CD28 co-stimulation. A phase 1 study in small cell lung cancer and other neuroendocrine tumors is underway.
A Treasury proposed rule would restrict certain US investments in biotechnology in China and other countries of concern, raising questions about how cross-border licensing and joint venture deals will be treated.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Advertisement
Advertisement
Trending on BioPharm International
1
Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
2
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
3
FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease
4
The BioPharm Brief: Gilead’s Oral IL-23R Bet, Roche’s Trispecific Deal, and Treasury’s Biotech Investment Proposal
5